News | November 14, 2025
Hormone therapy for menopause gets green light from FDA
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The antibody was designed and developed at Abzena’s Cambridge, UK,
Subscribe To Our Newsletter & Stay Updated
